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Abstract
Summary Rationale: Calcidiol can be employed to correct
vitamin D deficiency. Main results: Calcidiol administered at
daily and weekly regimens over a period of 3 months was able
to successfully raise 25-hydroxyvitamin D levels without al-
tering other markers related to bone and mineral metabolism.
Significance: Calcidiol supplementation is effective and safe.
Introduction The correction of vitaminD status is necessary to
maintain an optimal mineral and skeletal homeostasis. Despite
cholecalciferol (vitamin D3) is the most commonly used drug
for vitamin D supplementation, the more hydrophilic com-
pound calcidiol (25-hydroxyvitamin D3) can be employed at
daily, weekly, and monthly regimens to reach in the short term
the target levels of serum 25-hydroxyvitamin D [25(OH)D]. In
the administration of different doses of calcidiol pharmacoki-
netic study (ADDI-D study), the efficacy and safety of daily
and weekly dosages of calcidiol were tested.
Methods A total of 87 Caucasian, community-dwelling, post-
menopausal women, aged 55 years or older, with vitamin D
inadequacy (serum 25(OH)D levels <30 ng/ml, with mean
25(OH)D below 20 ng/ml, namely 16.5 ± 7.5 ng/ml) were
randomized to receive three different dosages of calcidiol:
20 μg/day, 40 μg/day, and 125 μg/week for 3 months. The
attained level of serum 25(OH)D was selected as primary
endpoint to assess efficacy, while other parameters of mineral
metabolism, (serum calcium, parathyroid hormone, phos-
phate, FGF23, urinary calcium, and markers of bone turnover)
were assessed as secondary endpoints to establish safety.
Results In all the three groups, serum 25(OH)D values signif-
icantly and promptly rose and plateaued above the 30 ng/ml
threshold remaining within safety interval after 14 days of
treatment, with similar efficacy for the similar daily and week-
ly dose regimens. The different dosages were also equally
effective in controlling secondary hyperparathyroidism. No
significant changes in calcium and phosphate metabolism
and in bone turnover markers were observed for any of the
treatments, confirming the safety of this compound.
Conclusions The results of this study demonstrate the short-
and mid-term efficacy and safety on core parameters of min-
eral metabolism of different daily or weekly dosages of
calcidiol when used to treat vitamin D inadequacy or deficien-
cy in postmenopausal women. Further studies are needed to
assess falls as primary outcome of calcidiol supplementation.
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Introduction
The measurement of serum levels of 25-hydroxyvitamin D
[25(OH)D], also referred to as calcidiol or calcifediol, still
represents the preferred biomarker for the assessment of vita-
min D status, reflecting the endogenous production and the
exogenous exposure [1–3]. Calcidiol values are inversely
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correlated with serum PTH. However, owing to several means
of calculating the point of maximal suppression of PTH by
25(OH)D, various thresholds (ranging from 12 to 50 ng/ml)
have been suggested [4–7]. Alternatively, given the diurnal
variation of serum PTH and dependency on recent calcium
intake and level of mobility [8], a 25(OH)D threshold for bone
health was assessed based on optimal hip bone mineral den-
sity [1] and reduction of fractures [9] pointing to a threshold of
24 to 30 ng/ml.
An optimal vitamin D status guarantees the maintenance of
an appropriate calcium and phosphate homeostasis. Levels of
25(OH)D less than 20 ng/ml (i.e., 50 nmol/l) have been sug-
gested as indicating vitamin D deficiency according to the
majority of published guidelines [1, 6]. Vitamin D deficiency
is very common worldwide, especially in seniors and osteopo-
rotic patients, who are at increased risk of fracture. In adults,
from a histological point of view, severe vitamin D deficiency
(<10 ng/ml) has been associated with osteomalacia, which,
due to impaired mineralization, can hamper bone strength
and neutralize or diminish the effectiveness of anti-
osteoporotic treatments [10]. Accumulated evidences indicate
a threshold level range of serum 25(OH)D between 21 and
30 ng/ml (53 to 75 nmol/l) to be recommended in fragile se-
niors at high risk for falls and fracture [9–11], especially before
commencing bone antiresorptive or anabolic therapy [1, 12].
Supplementation with vitamin D inactive precursors of the
biologically active vitamin D metabolite (i.e., 1,25(OH)2D or
calcitriol) is an efficient way to correct a poor vitamin D status
and restore an optimal mineral homeostasis [1, 13–17].
The most common form of vitamin D supplementation
used today is cholecalciferol, also known as native or parental
vitamin D3. The recommended daily dosage regimens are
usually not able to correct rapidly vitamin D inadequacy. A
recent pharmacokinetic study suggested that it takes about
68 days with the daily dose of 800 IU of cholecalciferol to
reach the optimal level plateau [15].
Therefore, high bolus doses (also referred to as mega
doses) of cholecalciferol have been suggested and employed
in order to achieve, in a relatively short time, the target levels
of serum 25(OH)D necessary to begin osteoporosis treatment
in subjects at increased risk of fracture [18]. Although the high
doses of cholecalciferol (up to 10,000 IU per day) are safe as
far as the classic side effects (hypercalciuria and hypercalce-
mia) are concerned [19, 20], unphysiologically high annual
doses of vitamin D (300,000 to 500,000 IU) have been asso-
ciated with an increased risk in falls and fractures [21, 22].
Notably, beyond the major endpoints such as falls and frac-
tures, recent studies also suggested that bolus doses of
100,000 IU vitamin D3 and above might increase bone resorp-
tion markers significantly and dose-dependently [23, 24].
Recently, a randomized controlled trial assessed the effect
of two higher monthly doses of vitamin D (monthly 60,000 IU
and 24,000 IU + 300 μg of calcidiol) in lowering the risk of
functional decline and falls in community-dwelling men and
women aged 70 or older with a prior fall event and compared
with a monthly standard dose of 24,000 IU vitamin D (equiv-
alent to 800 IU per day). Contrary to the expectations of the
authors, the higher monthly bolus doses did not improve low-
er extremity function superior to the standard monthly dose
and increase the odds of falling significantly despite raising
25(OH) levels more effectively [11]. These results have been
confirmed by a study carried out in a population of vitamin D
deficient elderly women (serum 25(OH)D less than 20 ng/ml)
randomized to receive daily supplements of cholecalciferol at
different dosages, with falls as primary outcome. In this group,
while medium doses of vitamin D (i.e., daily dosages of 1600,
2400, and 3200 IU) were proven to prevent falls with respect
to ineffective low doses (i.e., daily dosages of 400 and
800 IU), greater doses (i.e., daily dosages of 4000 and
4800 IU) leading to higher serum 25(OH)D concentrations
(>40–45 ng/ml) increased fall rate [25].
Based on these data and the trials outlined earlier on the
high annual doses, bolus applications of vitamin D adminis-
tered intermittently are not warranted in seniors at increased
risk of falling. Although no definitive conclusions can be
drawn so far on this finding and no causal relationship has
been demonstrated, it is nowadays not advisable to administer
large doses of cholecalciferol at large intervals of time, accord-
ing to most guidelines [1, 12]. Notably, higher daily doses of
vitamin D need further exploration.
Calcidiol, the direct precursor of calcitriol, can represent an
alternative strategy to enhance circulating serum 25(OH)D
levels [15–17, 26, 27]. Several pharmacokinetic studies per-
formed in the last four decades have demonstrated its hydro-
philic properties, leading to higher solubility in organic sol-
vents, lower trapping in the adipose tissues, smaller distribution
volume, and shorter half-life (10–13 days), when compared to
the parental compound cholecalciferol (30–45 days) [13, 26,
28]. The good predictability of achieved 25(OH)D levels in the
short term, along with the effective PTH suppression and man-
ageability in case of intoxication, may confirm the advantages
of calcidiol supplementation versus cholecalciferol [14, 16].
Moreover, greater affinity of calcidiol for vitamin D binding
protein (VDBP) allows a more efficient internalization in cells
expressing the megalin-cubilin system of endocytic receptors,
such as the parathyroids and the renal tissue [29].
The administration of calcidiol may be preferable in
several conditions [13]. An example is offered by the
alteration of liver cytochrome enzymes required for 25-
hydroxylation [14, 30]. In the case of intestinal malab-
sorption, especially when associated with and steator-
rhoea, calcidiol is better absorbed than cholecalciferol
[31]. In addition, since a PTH-mediated inhibition of liver
cytochrome isoforms has been shown in uremia, calcidiol
utilization, instead of cholecalciferol, has been proposed
for patients with chronic kidney disease [32].
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The pharmacokinetics of calcidiol and cholecalciferol has
been recently compared in a randomized, controlled parallel-
group study [15]. Calcidiol administered daily, weekly, or in
single bolus has been shown to be more effective and rapid in
rising serum 25(OH)D levels with respect to cholecalciferol
given at comparable doses daily (20 μg/day), weekly (140 μg/
week for 15weeks), or in single bolus (140μg), with no risk of
vitamin D intoxication [15]. Notably, the authors assessed also
several clinical endpoints providing evidence that calcidiol
given daily or weekly may be more effective in maintaining
or improving lower extremity function and lowering systolic
blood pressure among young postmenopausal women [16].
Calcidiol diluted in propylene glycol at a concentration of
150 μg/ml (5 μg calcidiol/drop) and administered as oral
drops is registered and included in the European
Pharmacopeia for the treatment of rickets due to vitamin D
deficiency in children, as well as for vitamin D deficiency,
osteomalacia, and spasmophilia in adults, plus additional in-
dications in the various EU Countries [13].
The aim of this study has been to further analyze and de-
scribe the therapeutic regimens of calcidiol in terms of inter-
vals of administration, and the mid-term effects on mineral
and bone metabolism.
Methods
The administration of different doses of calcidiol study
(ADDI-D study, EudraCT number: 2013-002648-10) is a
multicenter, randomized, open label, three-arm, parallel
group, and comparative phase III study. The study drug
was calcidiol (Didrogyl®, solution, containing 1.5 mg of
calcidiol and 10 ml propylene glycol in a dropper bottle,
one drop = 5 μg calcidiol), to be taken in the morning in
fasting state.
The primary objective of the study was to compare the
effects of three different therapeutic regimens of calcidiol on
the increase of circulating levels of serum 25(OH)D.
Secondary objectives were to compare the effects of three
different therapeutic regimens of calcidiol on changes of se-
rum and urinary levels of mineral and bone biomarkers as
compared at baseline.
The primary efficacy endpoint (primary variable) was rep-
resented by the attained circulating values of 25(OH)D at
3 months of treatment. Secondary efficacy endpoints (second-
ary variables) were the measurement of serum bone alkaline
phosphatase (BALP), parathyroid hormone (PTH),
1,25(OH)2D, VDBP, and 24-h urine calcium over 3 months
of treatment. Secondary safety endpoints were incidence of
adverse events (AEs), serum calcium (corrected), ionized cal-
cium, phosphate, creatinine, C-terminal telopeptides of type I
collagen (CTX), fibroblast growth factor 23 (FGF 23), 24-h
urinary calcium, and urinary deoxypiridinoline (DPD).
The study group was composed of Caucasian, community-
dwelling, postmenopausal women, aged 55 years or older
(years since menopause >2) with vitamin D inadequacy [i.e.,
serum 25(OH) D levels less than 30 ng/ml or 75 mmol/l],
adequate calcium intake (1000 mg/day), and BMI < 30, con-
secutively recruited in two Italian referral centers for osteopo-
rosis andmetabolic bone diseases at the University Hospital of
Florence, Florence, and University Hospital of Rome,
Umberto I, respectively. The local internal review board of
the two institutions approved the study. An informed consent
was obtained from each participant.
Potentially eligible women were subjected to an assess-
ment visit, consisting of medical history, clinical (vitals,
weight, height, physical examination including blood pressure
and pulse rate), and biochemical evaluations. An estimate of
calcium intake was performed by administering a specific nu-
tritional questionnaire [33].
Subjects were excluded on the basis of general criteria, as
well as specific medical and therapeutic conditions (progres-
sive major illness, severe malabsoption syndrome, IV stage
chronic kidney disease, Paget’s disease of bone, primary hy-
perparathyroidism/hypoparathyroidism, hypercalcemia, sar-
coidosis, hypercalciuria, intolerance to calcidiol, treatments
interfering with bone and mineral metabolism such as gluco-
corticoids, diuretics, lithium, immunosuppressants, antiretro-
viral therapy, and other drugs interfering with vitamin D ab-
sorption and catabolism). In particular, it was necessary for the
candidates not to be exposed either to cholecalciferol
(>400 IU/day in the previous month, doses >10,000 IU within
the previous 3 months, or doses >50,000 IU within the previ-
ous 12 months) or to calcidiol and active vitamin D analogs
during the 6 months prior to selection.
After the assessment visit, eligible subjects were random-
ized through a computer-based randomization system into
three groups: group 1, receiving oral calcidiol 20 μg
(Didrogyl® 4 drops) daily; group 2, receiving calcidiol
40 μg (Didrogyl® 8 drops) daily; and group 3, receiving
125 μg (Didrogyl® 25 drops) weekly. Thus, group 3 received
on a weekly basis a similar dose as compared to group 1,
taking calcidiol over 7 days. The 20 μg dosage was chosen
because of the equivalence (in μg) to 800 IU of cholecalcifer-
ol, which is still considered the standard daily dose of vitamin
D3 [15–17]. It was decided not to exceed 125 μg for safety
reason and possible side effects, since previous studies [15]
showed that the administration of 140 μg/week in a single
dose, although safe in terms of hypercalciuria and hypercalce-
mia, was followed by peaks in serum concentration of
25(OH)D nearly approaching 50 ng/ml possibly linked to
non-classical side effects such as falls or increase in bone
turnover markers [15, 23, 24]. Patients were evaluated at base-
line, and 7, 14, 21, 28, 60, and 90 days, afterwards. Adverse
events, compliance, and concomitant treatments were record-
ed at each time point.
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Serum 25(OH)D, VDBP, calcium, phosphate, albumin,
ionized calcium, creatinine, bone alkaline phosphatase,
and CTX were assayed at each visit. Serum PTH,
1,25(OH)2D, intact FGF23, alkaline phosphatase (AP), al-
bumin, total proteins, bilirubin, ASAT, ALAT, GGT, Na,
Cl, and K were assessed at baseline and at 90 days. Urinary
parameters such as 24-h urinary calcium, phosphate, and
creatinine and DPD were assessed at each time point.
Albumin and total proteins were determined for the calcu-
lation of corrected serum calcium, while AP, bilirubin,
ASAT, ALAT, GGT, Na, Cl, K, urinary phosphate, and
creatinine were assessed for safety issues. These latter pa-
rameters were not included in the endpoints of the study.
The determinations of serum 25(OH)D (vitamin D TOTAL
Assay, DiaSorin USA, Stillwater, MN, USA, competitive one-
step backfill chemiluminescence assay, with a measurement
range of 4–150 ng/ml and functional sensitivity of 4.0 ng/ml
or less; intra- and inter-assay precision of 8.9 and 12.8%, re-
spectively, with reported cross-reactivity values of 100% for
both 25-hydroxyvitamin D2 and 25-hydroxyvitaminD3), intact
FGF23 (ELISA, Immutopics, Inc., CA, USA; CV intra-assay
4.5%, CV inter-assay 11.5%), and VDBP (ELISA, DRG
Instruments GmbH, Germany; CV intra-assay 5.5%, CV in-
ter-assay: 12.5%) were performed on frozen samples and cen-
tralized at the University Hospital of Rome [for serum
25(OH)D samples, in a laboratory (no. 140) accredited to
Vitamin D Eternal Quality Assessment Scheme, DEQAS] and
University Hospital of Florence (for serum intact FGF23 and
VDBP samples). The measurements of BALP (immunoassay,
IDS-iSYS Multi-Discipline Automated System, UK), CTX
(electrochemiluminescent assay, Cobas 601, Roche
Diagnostics Gmb, Germany), DPD (chemiluminescent assay,
Immulite, 2000, Siemens, UK), PTH (electrochemiluminescent
assay, Cobas 601, Roche Diagnostics Gmb, Germany), and
1,25(OH)2D (chemiluminescent assay, IDS-iSYS, Belgium)
were carried out in central routine laboratory on frozen samples
at University Hospital of Florence. All the other measurements,
including ionized calcium, were carried out at local recruiting
centers; random samples were assayed in a central laboratory
for quality assurance.
All subjects were advised to maintain a systematic daily
calcium intake of 1000 mg/day from dietary sources. When
this was not achieved by diet only, calcium supplements
(500mg/day, to be taken at lunchtime) were also administered.
Based on the intention-to-treat principle, the full analysis
set (FAS) corresponds to patients who have taken at least one
dose of study treatment after randomization. The safety pop-
ulation consisted of all patients who received any study med-
ication and was based on the treatment they actually received.
For the primary variable [serum 25(OH)D], the absolute
change at the final visit in respect to baseline 25(OH)D has
been estimated in the FAS population using analysis of variance
(ANOVA). The model has included fixed effect terms for
treatment. Considering that the central laboratory evaluated all
main biochemical data and no evidence for center effect has
been evidenced in preliminary analyses, final analyses do not
take into account the center effect. Multiple comparison tests
for main level effects in the model have been carried out using
post hoc Bonferroni test. Sensitivity analyses on primary vari-
able has been conducted applying analysis of co-variance
(ANCOVA) on time profile using baseline data as co-variate
in order, analysis of co-variance (ANCOVA) on time profile
above the treatment response using baseline data as co-variate,
dosage treatment, visit, and dose-visit interaction. Student t test
has been used to evaluate intra-treatment change from baseline.
As far as secondary variables are concerned, the treatment
effect has been estimated in the FAS population, and only
biochemical relevant parameters have been processed with
ANOVA for repeated measures. The model included dosage
effect, visit, and dosage-visit interaction.
Safety analyses have been carried out on the safety popu-
lation. Laboratory parameters have been described using the
appropriate summary statistics at each visit stratified by treat-
ment. A potentially clinically significant abnormal value has
been evidenced.
Vital signs have been described by group of treatment. A
potentially clinically significant abnormal value has been
evidenced.
A sample size of 72 subjects was calculated to demonstrate
a between-factor effect (Cohen’s d) of 0.45 in an ANOVA
repeated measure analysis, considering alpha and beta levels
of 0.05, and the contrast between basic and final visit as pri-
mary end point. In order to be more conservative and taking
into account around 15% of drop-outs during the study, the
final sample size estimationwas 84 subjects (28 in each group).
Results
A total of 87 women with vitamin D inadequacy were ran-
domized to receive three different dosages of calcidiol. Three
patients did not assume any treatment and then were therefore
excluded from further analyses. Twenty-seven patients re-
ceived calcidiol at the dosage of 20 μg (4 drops)/day (dosage
1), 28 patients received calcidiol at the dosage of 40 μg (8
drops)/day (dosage 2), and 29 patients received calcidiol at the
dosage of 125 μg (25 drops) weekly (dosage 3).
The treatment groups were comparable for baseline demo-
graphic and clinical characteristics (age, age of menarche, age
of menopause, height, weight, BMI, and body surface area),
and calcium intake (including calcium as daily supplement for
patients not reaching 1000 mg/day, as specified above), with
no observed statistically significant difference for the different
parameters (Table 1). Regarding vitamin D status, almost two
thirds (62.1%) of the women showed levels of serum
25(OH)D less than 20 ng/ml, with a mean serum 25(OH)D
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levels of 16.5 ± 7.5 ng/ml and no significant difference be-
tween the treatment groups. Mean levels of serum 25(OH)D
were comparable and below 20 ng/ml, namely 15.1 ± 7.4 ng/
ml in group 1, 16.8 ± 6.6 ng/ml in group 2, and 16.4 ± 9.7 ng/
ml in group 3 (Supplementary Table 1).
No alterations in vital signs or clinical abnormalities were
recorded at the screening visit nor in the following
examinations.
In Fig. 1, the profiles of serum 25(OH)D concentration
attainedwith the three dose regimens of calcidiol are displayed.
The ANOVA on absolute change of 25(OH)D levels from
baseline (primary analysis) showed statistical difference be-
tween the final attained 25(OH) concentration at the end of
the study period versus baseline levels in each of the three
groups (p < 0.0001). Difference at day 90 in respect to baseline
has been confirmed by paired Student t test for all treatment
groups (p < 0.0001). Post hoc Bonferroni multiple comparison
evidenced statistical difference between dosage 1 and 2 (esti-
mated difference −23.44 with SE estimated 5.30 associated to
probability corrected level equal to <0.0001) and dosage 2 and
3 (estimated difference 28.46 with SE estimated 5.20 associat-
ed to probability corrected level equal to <0.0001); no
statistical difference has detected between dosage 1 and 3 (es-
timated difference 5.02 with SE estimated 5.30 associated to
probability corrected level equal to 1.0000). Sensitivity analy-
ses have confirmed results of the primary analysis. Analysis on
time profile has evidenced a statistical significant difference in
treatments response during time at the various time points for
each treatment group (ANOVA for repeated measures:
p < 0.0001 for each value versus respective baseline).
Thus, all dosage schemes enabled a significant increase in
serum 25(OH)D levels at the end of treatment period with
restrained variability, as demonstrated by 95% confidence
limits. Considering two populations of women, those with
baseline serum 25(OH)D levels below 20 ng/ml and those
with serum 25(OH)D levels between 20 and 30 ng/ml, no
differences were observed in terms of absolute percentual in-
crease in serum 25(OH)D levels (final versus baseline) be-
tween the two categories of patients for each treatment group
(+168.2 and +203.6% in group 1, +297.0 and 299.3% in
group 2, 161.6 and 152.5% in group 3, respectively).
After 14 days of treatment, the majority (75%) of patients
reached lower limit for serum 25(OH)D sufficiency (i.e.,
20 ng/ml); then, a further increase was observed, maintaining
the serum concentration in the classical safety window (30–
100 ng/ml). While 25(OH)D levels were similar for the groups
receiving 20 μg/day or 125 μg/week at each time point, with a
final attained 25(OH)D of 49.3 ± 19.5 and 46.4 ± 15 ng/ml,
respectively, they almost doubled in the group supplemented
with 40 μg/day, reaching a mean 25(OH)D of 74.8 ± 22.5 ng/
ml. Moreover, no difference was observed in serum 25(OH)D
concentrations between 30 and 90 days of treatment, indicating
a plateau phase during calcidiol administration in the short-to-
medium term.
Figures 2, 3, 4, to 5 show the time course of different
serum and urinary biochemical and hormonal markers
(reported in detail in Supplementary Tables 1 and 2).
Serum total and ionized calcium remained within the nor-
mal range for the duration of the study in the three groups
of patients. As demonstrated by ANOVA for repeated mea-
sures, no statistical differences between the three treatment
groups and versus baseline were observed for serum total
calcium and ionized calcium, despite a statistical difference
was shown for ionized calcium for visit term (F val-
ue = 5.99, Prob > F < 0.0001), which should be interpreted
as consequence due to the relevant fluctuation of values at
day 21 (Supplementary Table 1, Fig. 2a, b).
Serum phosphate, creatinine, and markers of bone turnover
(BALP and CTX) stayed within the normal range in the three
groups. No peak concentrations in bone turnover markers
were observed. ANOVA for repeated measures confirmed
no differences between treatments, despite significant fluctu-
ation during the visits for serum phosphate (F value = 2.27,
Prob > F = 0.0451), serum creatinine (F value = 1.27,
Prob > F = 0.2825) and markers of bone turnover such as
Table 1 Baseline characteristics of women in the three randomization
groups
Treatment group of calcidiol n Mean ± SD
Age (years) 20 μg/day 27 69.9 ± 8.0
40 μg/day 28 64.4 ± 6.8
125 μg/week 29 66.2 ± 7.8
Age of menarche 20 μg/day 27 12.6 ± 1.6
40 μg/day 28 12.4 ± 1.5
125 μg/week 29 13.1 ± 1.7
Age of menopause 20 μg/day 27 47.6 ± 5.8
40 μg/day 28 49.3 ± 5.6
125 μg/week 29 49.0 ± 5.3
Height (m) 20 μg/day 27 160.0 ± 7.4
40 μg/day 28 160.9 ± 6.7
125 μg/week 29 158.7 ± 6.3
Weight (Kg) 20 μg/day 27 63.9 ± 7.3
40 μg/day 28 64.0 ± 8.6
125 μg/week 29 62.9 ± 9.9
BMI (Kg/m2) 20 μg/day 27 25.0 ± 3.0
40 μg/day 28 24.7 ± 2.6
125 μg/week 29 25.0 ± 3.8
BSA (m2) 20 μg/day 27 1.7 ± 0.1
40 μg/day 28 1.7 ± 0.1
125 μg/week 29 1.7 ± 0.1
Calcium intake 20 μg/day 27 1035.7 ± 323.6
(mg/day) 40 μg/day 28 912.8 ± 386.4
125 μg/week 29 964.6 ± 426.7
n number of subjects, BMI body mass index, BSA body surface area
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BALP (F value = 5.00, Prob > F = 0.0002) and CTX (F
value = 2.91, Prob > F = 0.0128) (Supplementary Table 1,
Fig. 2c, d, Fig. 3a, b).
Hormonal parameters were determined at baseline and final
evaluation (Supplementary Table 2). Serum levels of PTH,
1,25(OH)2D and intact FGF23 did not vary among the differ-
ent treatments (ANOVA). While 1,25(OH)2D and intact
FGF23 levels remained stable during calcidiol supplementa-
tion in the three groups of treatment (final versus baseline
serum 1,25(OH)2D: p = 0.44, p = 0.46, and p = 0.99 for dosage
1, 2, and 3, respectively; final versus baseline serum FGF23:
p = 0.47, p = 0.40, and p = 0.43 versus baseline for dosage 1, 2,
and 3, respectively), PTH significantly decreased over the
90 days (final versus baseline serum PTH: p < 0.0001,
p < 0.0001, and p = 0.0005 for dosage 1, 2, and 3, respective-
ly), (Fig. 4a, b). Regarding VDBP (Supplementary Table 1,
Fig. 4c), ANOVA for repeated measures showed a significant
steady increase during the first 4 weeks of treatment (F val-
ue = 13.25, Prob > F < 0.0001) (Fig. 4c).
Urinary parameters have been evaluated for safety issues.
ANOVA for repeated measures confirmed no differences be-
tween treatments despite significant fluctuation during the study
Fig. 2 Time profile of the values of serum calcium (mg/dl) (panel a),
ionized calcium (mg/dl) (panel b), phosphate (mg/dl) (panel c), and
creatinine (mg/dl) (panel d) under different dose regimens of calcidiol
at various time points (mean ± SE); normal range is indicated between
the dotted lines
Fig. 1 Time profile of the
response of serum 25(OH)D (ng/
ml) to different dose regimens of
calcidiol at various time points
(mean ± SE); the dotted lines
indicate serum levels of 25(OH)D
vitamin D sufficiency/adequacy
by different guidelines (i.e., 20
and 30 ng/ml) (*p < 0.05 and
**p < 0.001 versus baseline for all
treatment groups)
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for 24-h urinary calcium (F value = 8.88, Prob > F < 0.0001)
(Supplementary Table 1) (Fig. 5). Although a steady increase in
urinary calcium was observed during the treatment with the
three dosage regimens, there was no evidence of hypercalciuria
(i.e., calcium >300mg/24 h). Indeed, urinary calcium plateaued
between 30 and 90 days of treatment. Twenty-four-hour urinary
phosphate, 24-h urinary creatinine, and urinary DPD did not
differ between the different dose regimens (Supplementary
Table 1).
Other biochemical parameters have been evaluated both for
efficacy and safety survey of patient status. No relevant
changes were observed for serum alkaline phosphatase, albu-
min, total proteins, ASAT, ALAT, GGT, Na, Cl, and K (data
not shown).
Throughout the study, only four events have been detected,
one per patient: three at center 1 (patient no. 20, dosage 40 μg/
day; patient no. 30, dosage 20 μg/day; patient no. 33, dosage
125 μg/day, and patient no. 34, dosage 125 μg/day) and one at
center 2 (patient no. 41, dosage 125 μg/day). The three pa-
tients at center 1 reported a flu episode, while the patient at
center 2 was found to be hypercalcemic in one occasion; this
episode was considered Bpossibly^ related to the treatment.
All other events were not considered to be drug-related.
Discussion
The ADDI-D study extends previous observations on the ef-
ficacy of calcidiol when employed in vitamin D supplemen-
tation for vitamin D inadequacy in postmenopausal women
with mean serum 25(OH)D levels below 20 ng/ml [15–17].
Moreover, for the first time, the effects of three different
calcidiol regimens on core parameters of bone and mineral
homeostasis in postmenopausal women with vitamin D inad-
equacy (i.e., serum 25(OH)D levels less than 30 ng/ml) have
been assessed. The results confirm calcidiol’s prompt efficacy
in correcting vitamin D status and underline its safety, at least
in the short/medium term, also in regard to some non-classi-
cal, unwanted adverse events (e.g., alterations in bone turn-
over markers or increased fall rate) observed during supple-
mentation with native vitamin D [11, 21, 22, 25].
Calcidiol, which is also the circulating form of vitamin D as
well as the best marker of vitamin D status, has been marketed
in Europe for vitamin D supplementation in several conditions
[13, 14]. Osteomalacia, the mineralization defect due to vita-
min D deficiency, is its main therapeutic indication in adults.
Especially in older individuals, this condition can coexist with
an alteration of bone microarchitecture (namely osteoporosis).
Calcidiol significantly decreases the osteoid volume and sur-
face and greatly increases the front of calcification, normaliz-
ing biological parameters (serum calcium, phosphorus, AP)
more efficiently than other vitamin D metabolites [13, 14].
When administering 25(OH)D, this metabolite enters the
circulation and hence bypasses liver metabolism. This, together
with peculiar chemical characteristics of calcidiol (greater po-
larity, unusual for a steroidal compound) and its consequent
pharmacokinetic properties, make this drug preferable when a
rapid replenishment of 25(OH)D reservoir and/or additional
potency for attaining desired amounts of 25(OH)D are required.
These peculiar properties have made calcidiol widely used
as vitamin D supplement, as demonstrated by the analysis of
regional administrative pharmaceutical databases [34].
In this study, calcidiol has been administered at three dif-
ferent regimens: two daily treatments of 20 and 40 μg, respec-
tively, and a weekly treatment of 125 μg, similar to the calcu-
lated cumulative dose of the lower daily dosage. In all the
three groups, serum 25(OH)D values significantly and
promptly rose above the 20 ng/ml threshold so that the major-
ity of subjects were vitamin D repleted after just 14 days of
treatment. This can be exploited particularly when vitamin D
status has to be optimized in a short interval of time, for ex-
ample when antifracture therapy has to be undertaken in sub-
jects at high risk for fracture (e.g., after a major fragility frac-
ture or when commencing glucocorticoid therapy). The rapid-
ity in correcting profound vitamin D deficiency with overt or
insidious osteomalacia makes calcidiol a good alternative to
the mega doses of parental vitamin D3, recently linked to
increased falls and fractures [21, 22], since the non-
Fig. 3 Time profile of bone turnover markers [serumBALP (μg/l) (panel
a) and CTX (ng/ml) (panel b) under different dose regimens of calcidiol
at various time points (mean ± SE); normal range is indicated between the
dotted lines
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physiological, abnormal higher peaks in the concentration of
25(OH)D are avoided. Because calcidiol is more powerful in
attaining the desired serum 25(OH)D level and due to its
smaller volume of distribution, it can be proposed as a better,
active vitamin D precursor for obese individuals, in whom
massive doses of cholecalciferol must be employed to reach
the threshold of 30 ng/ml [14, 35].
The baseline vitamin D status has a major influence on the
percentual increase in serum 25(OH)D during cholecalciferol
supplementation [33]. This does not seem to be true also for
calcidiol, since, as demonstrated in the ADDI-D study, the
increase in vitamin D levels obtained by calcidiol administra-
tion does not depend on initial vitamin D status. Indeed, the
percentual gain in serum 25(OH)D levels comparable for
womenwith baseline 25(OH)D less than 20 ng/ml and women
with 25(OH)D comprised between 20 and 30 ng/ml.
Nonetheless, this observation requires further studies.
The similarity of efficacy of the daily and weekly dose
regimens (i.e., 20 μg/day and 125 μg/week, respectively) in
terms of attaining sufficient levels of 25(OH)D shown in this
study confirm previous findings [15], indicating that adminis-
tering calcidiol every day or administering an equal (140 μg)
[15] or similar (125 μg) amount once a week or monthly [27]
results in equal effectiveness with respect to attaining desired
25(OH)D levels. The efficacy of the lower dose regimens also
demonstrates that there is no need to further increase the dos-
age in non-obese subjects to correct vitamin D status for op-
timizing mineral homeostasis. Nonetheless, the pharmacoki-
netic profile of the compound shows the attainment of a pla-
teau of serum 25(OH)D levels in the long interval between 30
and 90 days of treatment, which is well below the upper limit
of classical toxicity (i.e., hypercalciuria and hypercalcemia),
even when administered at higher dose (40 μg/day).
Nonetheless, given the increasing evidence of non-classical
toxic effects (i.e., increased fall rate) for attained levels of
serum 25(OH)D above 50 ng/ml [11, 25], the higher dosages
Fig. 4 Time profile of serum PTH (pmol/l) (panel a), intact FGF23 (pg/
ml) (panel b), 1,25(OH)2D (ng/ml) (panel c), and VDBP (mg/dl) (panel
d), and to different dose regimens of calcidiol at various time points
(mean ± SE); normal range is indicated between the dotted lines
(*p < 0.05 and **p < 0.001 versus baseline for all treatment groups)
Fig. 5 Time profile of urinary calcium (mg/24 h) under different dose
regimens of calcidiol at various time points (mean ± SE) (*p < 0.05 versus
baseline for all treatment groups)
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of calcidiol (i.e., 40 μg/day) should be possibly avoided, par-
ticularly in frail individuals at high risk of falling and related
consequences [36].
The results of the ADDI-D study suggest a good safety and
manageability of this compound at lower dosages in clinical
practice, without the need of close monitoring serum
25(OH)D in the short-medium term. Indeed, levels of VDBP
increased steadily within the first 30 days, before the plateau
in 25(OH)D concentrations during daily administration of
40 μg and weekly administration of 125 μg. This may repre-
sent a buffering of the homeostatic vitamin D system itself to
avoid dangerous increase in biologically active 25(OH)D.
In addition, a good predictability of achieved serum
25(OH)D levels has been observed, with increases by twofold
though the administration of double doses of daily calcidiol.
Calcidiol has proven to be safe when administered at daily,
weekly, monthly, or every other week [27] dose regimens. It is
commonly used in clinical practice, without risk of vitamin D
intoxication (i.e., hypercalciuria and hypercalcemia). Indeed,
the attained 25(OH) levels are far below what is considered as
the upper limit of normal values (i.e., 100 ng/ml) as indicated
by most laboratories in order to avoid the vitamin D-related
classic toxic effects, namely hypercalciuria and hypercalce-
mia. Total and ionized calcium levels were stable up to 90 days
of treatment. Moreover, serum phosphate and creatinine
remained within the normal range, along with urinary markers
and routine biochemical tests, and no difference was observed
between different dosages, beside expected physiological
fluctuations within the study period.
Regarding safety issues, this study for the first time has also
assessed the effect of calcidiol on several additional markers
of mineral metabolism.
The increase of markers of bone turnover has been sug-
gested as possible mechanisms to explain unwanted non-
classic side effect of cholecalciferol [23, 24]. In this study,
no increase of markers of bone turnover (such as serum
BALP, CTX, and urinary DPD) was observed for any of the
treatments with calcidiol within the whole interval of admin-
istration. Furthermore, in a previous study utilizing a monthly
dose of 500 μg calcidiol, a decrease of bone alkaline phospha-
tase was even observed [27].
As expected, a decrease of serum PTH levels as well as an
increase of 25(OH)D concentration was observed. Notably,
however, the different dosages were equally effective in con-
trolling secondary hyperparathyroidism. Alterations of
FGF23, phosphate metabolism, and 1,25(OH)2D have been
indicated as possible mediators of non-classic toxic effects
of cholecalciferol and/or possibly counteracting the effects
of vitamin D [37, 38]. No differences in serum intact
FGF23, phosphate, or 1,25(OH)2D concentrations were ob-
served during daily or weekly calcidiol administration, further
underlining the safety of this compound regarding potential,
non-classic unwanted events.
Overall, the results of this study confirm the efficacy and
safety of calcidiol, the direct precursor of calcitriol, when
used, at least in the short/medium term, to treat vitamin D
inadequacy or deficiency in postmenopausal women.
Given the growing recent evidence of increased number of
falls for higher dosages of cholecalciferol leading to serum
25(OH)D above 50–60 ng/ml [11, 25], caution has to be used
before prescribing higher dosages of calcidiol (i.e., 40 μg/
day), particularly in subjects at high risk of falling, even if
an increased risk of falling has not still been demonstrated
for calcidiol supplementation. Indeed, no data on falls are
available during calcidiol supplementation, while a better
muscular performance has been demonstrated [16, 39]. We
acknowledge that not having included fall assessment in the
safety analysis is a limitation of our study. In this respect,
further mid- and long-term studies are necessary in this field,
having falls as primary outcome, particularly in at-high-risk
individuals.
Conclusions
The study hereby presented demonstrates, for the first time,
the efficacy of calcidiol as well as its safety on multiple pa-
rameters related to mineral and bone metabolism in the short-
medium term.
More studies are needed to further assess the calcidiol phar-
macokinetics properties in the long term, along with unique
properties of the compound that have not yet been fully rec-
ognized, such as musculoskeletal effects. Indeed, some ran-
domized controlled trials have demonstrated increased muscle
performance in postmenopausal women supplemented with
calcidiol at usual doses with respect to cholecalciferol [16,
39], although the risk of falling during calcidiol supplementa-
tion has not been assessed yet as a primary outcome. These
properties make calcidiol a good alternative to cholecalciferol
in the treatment of the widespread vitamin D deficiency and
related musculoskeletal consequences (osteomalacia, falls,
and fractures), and even the supplement of choice when spe-
cific conditions hamper the efficacy of parental vitamin D.
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